Screening assays for compounds that cause apoptosis
This invention relates to methods of screening for compounds capable of inducing apoptosis in certain tumor cells. The invention also relates to compounds identified by such methods. In addition, the invention relates to methods for the in vitro diagnosis of Xeroderma pigmentosum and compounds useful in these methods.
1. A method for identifying a compound that modulates XPB or XPD helicase-dependent p53-mediated apoptosis comprising:
(a) providing a biologically active p53 polypeptide, and a XPB or XPD helicase polypeptide,
(b) contacting a compound suspected of inducing XPB or XPD helicase-dependent p53-mediated apoptosis with the polypeptides of step (a)
(c) detecting whether or not the compound is capable of specifically inhibiting binding of the p53 polypeptide to the XPB or XPD helicase, wherein a compound that specifically inhibits the binding of the p53 polypeptide to the XPB or XPD helicase is a compound that modulates helicase-dependent p53-mediated apoptosis.
2. The method of claim 1 , further comprising contacting the polypeptides with a compound that inhibits binding of p53 to XPB or XPD.
3. The method of claim 2 , wherein the compound that inhibits binding of p53 to XPB or XPD is HBX.
4. The method of claim 1 , further comprising
(d) determining whether the compound suspected of inducing helicase-dependent p53-mediated apoptosis can inhibit helicase activity, wherein a compound that inhibits XPB or XPD helicase activity is a compound that modulates helicase- dependent p53-mediated apoptosis.
5. The method of claim 4 , wherein the helicase polypeptide is present as part of a TFIIH transcription complex.
6. The method of claim 1 , wherein the p53 polypeptide and the helicase polypeptide are each introduced into a cell.
7. The method of claim 6 , wherein at least one of the p53 polypeptide or the helicase polypeptide is a native polypeptide.
8. The method of claim 6 , wherein the p53 polypeptide is a wild-type p53 polypeptide.
9. The method of claim 6 , wherein the helicase polypeptide is a mutant helicase polypeptide.
10. The method of claim 6 , wherein the cell is a member selected from the group consisting of: a fibroblast cell, an epithelial cell, and a hematopoietic cell.